Zacks Investment Research downgraded shares of UCB (NASDAQ:UCBJF) from a strong-buy rating to a hold rating in a research note published on Tuesday morning.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
TRADEMARK VIOLATION WARNING: “UCB (UCBJF) Cut to Hold at Zacks Investment Research” was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.thestockobserver.com/2017/10/13/ucb-ucbjf-cut-to-hold-at-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.